66 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
RDY Dr. Reddy's Laboratories Ltd $35.7 $5.93B N/A
Article Searches
Is it Apt to Foray Into the Indian Stock Market?: An Analysis http://www.zacks.com/stock/news/527926/is-it-apt-to-foray-into-the-indian-stock-market-an-analysis?cid=CS-ZC-FT-analyst_blog|investment_ideas-527926 Sep 20, 2019 - The government of India unveils an array of concessions to spur the economy. This in turn will slash most corporate taxes to 22% while new manufacturers will pay even a lower corporate tax rate of 15%.
J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use http://www.zacks.com/stock/news/526368/jjs-prostate-cancer-drug-gets-fda-nod-for-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-526368 Sep 19, 2019 - J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.
Zynerba Releases Data on Epilepsy Candidate, Stock Down http://www.zacks.com/stock/news/526215/zynerba-releases-data-on-epilepsy-candidate-stock-down?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-526215 Sep 19, 2019 - Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
Top Ranked Momentum Stocks to Buy for September 17th http://www.zacks.com/commentary/522889/top-ranked-momentum-stocks-to-buy-for-september-17th?cid=CS-ZC-FT-zacks_#1_rank_additions-522889 Sep 17, 2019 - Top Ranked Momentum Stocks to Buy for September 17th
Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug http://www.zacks.com/stock/news/427399/dr-reddys-reports-positive-top-line-data-on-psoriasis-drug?cid=CS-ZC-FT-427399 Jun 10, 2019 - Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady http://www.zacks.com/stock/news/425808/biomarins-vimizim-wins-nod-in-china-for-rare-genetic-malady?cid=CS-ZC-FT-425808 Jun 06, 2019 - BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.
New Strong Sell Stocks for May 22nd http://www.zacks.com/stock/news/417826/new-strong-sell-stocks-for-may-22nd?cid=CS-ZC-FT-417826 May 22, 2019 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Dr. Reddy's Laboratories Ltd (RDY) CEO Gunupati Prasad on Q4 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4264996-dr-reddys-laboratories-ltd-rdy-ceo-gunupati-prasad-q4-2019-results-earnings-call-transcript?source=feed_tag_india May 17, 2019 - Dr. Reddy's Laboratories Ltd (NYSE:RDY) Q4 2019 Earnings Conference Call May 17, 2019, 08:30 ET Company Participants Amit Agarwal - Director, Finance, FP&A & IR Gunupati Prasad - CEO Saumen Ch
Dr. Reddy's (RDY) Earnings Rise in Q4, Revenues Beat http://www.zacks.com/stock/news/415513/dr-reddys-rdy-earnings-rise-in-q4-revenues-beat?cid=CS-ZC-FT-415513 May 17, 2019 - Dr. Reddy's earnings and sales increase year over year in the fourth quarter of fiscal 2019.
Supernus' ADHD Candidate Positive in 4th Phase III Study http://www.zacks.com/stock/news/368648/supernus-adhd-candidate-positive-in-4th-phase-iii-study?cid=CS-ZC-FT-368648 Apr 01, 2019 - Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.

Pages: 1234567

Page 1>